FRPT enters the post-earnings period with shorts sitting near cycle highs and the stock having shed 8% on the week — a setup that rewards watching how short positions respond to what the company just said.
Short interest in Freshpet has been one of the defining features of this trade for weeks. It climbed sharply through mid-April, reaching above 14% of free float on April 13 before easing back. The latest reading — 12.8% of FF — reflects a modest retreat, but the broader picture remains elevated: a month ago short interest was closer to 10.8%, meaning shorts have added roughly two percentage points of float exposure since early April. That kind of build is not noise. FINRA's fortnightly figure puts days to cover near 4.6, meaning a meaningful unwinding would take the better part of a week's volume to execute.
The borrow market is not signalling distress. Cost to borrow is running just below 0.5% — cheap by any measure — and availability remains wide, consistent with a stock where there is no shortage of lending supply. Shorts are not being squeezed out; they are sitting with comfortable borrow at low cost. Options positioning reinforces that calm: the put/call ratio is 0.69, fractionally below its 20-day average of 0.70 and within a tight range for weeks. That is a far cry from the 52-week high of 2.15. Neither the options market nor the borrow market is flashing stress.
The analyst community is cautiously tilted positive, though targets have been drifting lower. The Street has trimmed price targets at several firms over the past month — Jefferies, Stifel, BofA Securities, Wells Fargo, and JPMorgan all shaved numbers, while DA Davidson and Benchmark moved theirs higher. The mean target of $84.44 implies meaningful upside from the current price of $60.17, but the gap between the bulls (targets above $90 at Benchmark and DA Davidson) and the cautious hold-rated names (Deutsche Bank at $62, JPMorgan at $66) is wide. Bulls argue Freshpet will exceed FY26 sales guidance, citing fresh-food pet category durability, the Costco Kirkland tie-up, and household penetration runway. Bears point to premium pet food competition from The Farmer's Dog and JustFoodForDogs eroding share, and rising distribution costs from the new channel push. EPS momentum factor scores rank in the 75th–85th percentile — the company has consistently beaten estimates — while forward EPS growth sits near the bottom of its peer universe at the 6th percentile, a tension between historical execution and future-year expectations. The EV/EBITDA multiple has contracted roughly one turn over the past month to 13.9x, which is not demanding if the growth case holds.
Institutional holders are broadly constructive. BlackRock recently added 144,000 shares to reach 11.75% of the company. Wasatch Advisors, a long-running growth-oriented holder, built a further 204,000 shares to sit at 8.4%. William Blair added 463,000 shares in Q1. The ownership base reads as patient growth money rather than speculative fast money, which helps explain why borrow availability is loose — long-only holders are willing lenders. Insider activity is less meaningful: the March 13 cluster of executive sells were small in scale and appear routine (the CEO sold just over 2,500 shares at $76.60). The net insider position over 90 days is a marginal positive at about $760,000 net purchased, but the individual trades carry significance scores of just 1 out of 10.
The next formal test arrives June 10, when Freshpet is next scheduled to report. The May 4 earnings release already produced a 7.6% single-day drop. The stock is now trading at $60.17 — well below the prices at which insiders sold in March and below every analyst's price target in the recent-changes list. What to watch is whether the elevated short interest — still two percentage points above where it started April — begins to reverse now that Q1 numbers are in the open, or whether shorts use any relief rally to add further.
See the live data behind this article on ORTEX.
Open FRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
